

Unaudited consolidated financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter ended 30 June 2014 prepared in compliance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB)

All amounts in Indian Rupees lakhs, except share data

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Net Income from Sales and Services	351,754	348,090	284,492	1,321,703
2	Cost of Sales and Services				
	a) (Increase) / decrease in stock-in-trade and work-in-progress	(6,930)	(7,779)	(11,875)	(33,094)
	b) Consumption of raw materials	66,875	74,606	65,583	273,402
	c) Purchase of traded goods	18,488	16,390	21,296	76,797
	d) Other expenditure	64,882	65,650	59,296	246,583
3	Gross Profit (1 - 2)	208,439	199,223	150,192	758,015
4	Selling, General and Administrative expenses	106,789	103,073	87,936	387,830
5	Research and Development expenses	38,753	39,848	24,297	124,023
6	Other (income) / expense, net	(1,848)	(2,263)	(3,756)	(14,159)
7	Operating profit (3) - (4 + 5 + 6)	64,745	58,565	41,715	260,321
8	Finance (expense) / income, net	4,809	1,634	(699)	3,995
9	Share of profit of equity accounted affiliate, net of income taxes	534	484	355	1,741
10	Profit before tax (7+8+9)	70,088	60,683	41,371	266,057
11	Tax expense	15,049	12,523	5,278	50,937
12	Net Profit after tax (10-11)	55,039	48,160	36,093	215,120
13	Extra-ordinary items (net of tax expense)	-	-	-	-
14	Net Profit for the period / year (12 - 13)	55,039	48,160	36,093	215,120
15	Net Profit attributable to:				
	- Equity holders of the Company	55,039	48,160	36,099	215,145
	- Non-controlling interest	-	-	(6)	(25)
16	Paid-up equity share capital (Face value of Rs. 5/- each)	8,517	8,505	8,503	8,505
17	Securities premium, retained earnings, share based payment reserve and other components of equity				899,541
18	Earnings per share before and after extra-ordinary items (in Rupees) per Rs. 5/- share				
	- Basic	32.34	28.31	21.25	126.52
	- Diluted	32.24	28.22	21.17	126.04
		(Not annualised)	(Not annualised)	(Not annualised)	
19	Public shareholding *				
	- Number of shares	95,472,936	96,048,821	97,484,533	96,048,821
	- Percentage of shareholding	56.05	56.47	57.32	56.47
20	Promoters and promoter group shareholding				
	a) Pledged / Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	43,417,812	43,417,812	43,417,812	43,417,812
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the Company)	25.49	25.52	25.53	25.52
21	Details of items exceeding 10% of total expenditure				
	- Employee cost	71,643	68,152	55,697	249,364

*Public Shareholding as defined under Clause 40A of the Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt holders)

Segment reporting (Consolidated)

All amounts in Indian Rupees lakhs

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment wise revenue and results:				
	Segment revenue :				
	a) Pharmaceutical Services and Active Ingredients	73,454	83,175	68,833	295,750
	b) Global Generics	290,026	273,175	219,025	1,051,636
	c) Proprietary Products	3,059	5,561	3,191	17,783
	d) Others	3,293	2,945	3,594	12,545
	Total	369,832	364,856	294,643	1,377,714
	Less: Inter-segment revenue	18,078	16,766	10,151	56,011
	Net Revenue from operations	351,754	348,090	284,492	1,321,703
	2	Segment results :			
Gross Profit from each segment					
a) Pharmaceutical Services and Active Ingredients		12,334	13,616	11,133	48,476
b) Global Generics		192,809	180,552	134,824	691,490
c) Proprietary Products		2,443	4,875	2,815	16,062
d) Others		853	180	1,420	1,987
Total		208,439	199,223	150,192	758,015
Less: Other un-allocable expenditure, net of other income		138,351	138,540	108,821	491,958
Total profit before tax		70,088	60,683	41,371	266,057

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at Cost.

Segmental Capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Notes:

1 Investor Complaints

Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed off during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

- The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 30 July 2014. The above financial results have been prepared from the consolidated financial statements, which are prepared in accordance with International Financial Reporting Standards and its interpretations (IFRS), as issued by the International Accounting Standards Board (IASB).
- The Securities and Exchange Board of India (SEBI) issued a circular dated 5 April 2010 permitting listed entities having subsidiaries to voluntarily submit the Consolidated Financial Statements as per IFRS. Consequent to this, the Company has voluntarily prepared and published unaudited Consolidated Financial Statements as per IFRS.
- The results for the quarter ended 30 June 2014 have been subject to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.
- 5 Unaudited financial results of Dr. Reddy's Laboratories Limited (Standalone Information) prepared as per IGAAP**

All amounts in Indian Rupees lakhs

Particulars	Quarter ended			Year ended
	30.06.2014	31.03.2014	30.06.2013	31.03.2014
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Total income from operations	269,048	261,512	182,162	972,805
Profit from ordinary activities before tax	78,168	59,714	8,336	245,439
Profit from ordinary activities after tax	60,275	47,143	6,486	193,284

Note:

The unaudited standalone financial results for the quarter ended 30 June 2014 are available on the Stock Exchange's website : www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.

By order of the Board
For Dr. Reddy's Laboratories Limited

G V Prasad
Co-Chairman, Managing Director
& Chief Executive Officer

Place: Hyderabad
Date: 30 July 2014